Why the study?
What is the absolute risk of venous thrombosis associated with various known thrombophilic defects in relatives of patients with thrombosis?
What is the absolute risk of venous thrombosis associated with various known thrombophilic defects in relatives of patients with thrombosis?
Thrombophilia testing should focus on hereditary deficiencies of antithrombin, protein C, and protein S in patients with a first venous thrombosis at a young age or with a strong family history, due to their significantly higher absolute thrombotic risk.
Answers are grounded in this paper and cite their sources.
May guide selective testing toward antithrombin, protein C, and protein S deficiencies; extends absolute risk data in relatives.
Thrombophilia screening is controversial. In a retrospective family cohort, where probands had thrombosis and a thrombophilic defect, 2479 relatives were tested for thrombophilia. In antithrombin-, protein C-, and protein S-deficient relatives, annual incidences of venous thrombosis were 1.77% (95% CI, 1.14-2.60), 1.52% (95% CI, 1.06-2.11), and 1.90% (95% CI, 1.32-2.64), respectively, at a median age of 29 years and a positive family history of more than 20% symptomatic relatives. In relatives with factor V (FV) Leiden, prothrombin 20210G>A, or high FVIII levels, these were 0.49% (95% CI, 0.39-0.60), 0.34% (95% CI, 0.22-0.49), and 0.49% (95% CI, 0.41-0.51), respectively. High FIX, FXI, and TAFI, and hyperhomocysteinemia were not independent risk factors. Annual incidence of major bleeding in antithrombin-, protein C-, or protein S-deficient relatives on anticoagulants was 0.29% (95% CI, 0.03-1.04). Cumulative recurrence rates in relatives with antithrombin, protein C, or protein S deficiency were 19% at 2 years, 40% at 5 years, and 55% at 10 years. In relatives with FV Leiden, prothrombin 20210G>A, or high levels FVIII, these were 7%, 11%, and 25%, respectively. Considering its clinical implications, thrombophilia testing should address hereditary deficiencies of antithrombin, protein C, and protein S in patients with first venous thrombosis at young age and/or a strong family history of venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Lijfering et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: